MedTrace Logo

Urinary KIM-1 After Vancomycin or Linezolid Administration

NCT02067390 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-02-20

No results posted yet for this study

Summary

Acute renal injury is a common complication of critical illness. Drug induced renal insult compounds the degree of injury in many patients, and a great deal of research has focused on prevention of this complication. Traditional biomarkers of renal injury like serum creatinine and blood urea nitrogen content fail to consistently predict harm among patients at risk. Kidney Injury Molecule 1 (KIM-1) will be studied as a biomarker of renal injury.

Conditions

Sponsors & Collaborators

  • Midwestern University

    lead OTHER

Principal Investigators

  • Marc H Scheetz, PharmD · Northwestern Memorial Hospital / Midwestern University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067390 on ClinicalTrials.gov